• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    7/19/24 4:30:23 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email
    SC 13D/A 1 sc13da207422010_07192024.htm AMENDMENT NO. 2 TO SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 2)1

    Inventiva S.A.

    (Name of Issuer)

    Ordinary Shares, nominal value €0.01 per share

    (Title of Class of Securities)

    46124U107

    (CUSIP Number)

    JAMES KRATKY

    BVF PARTNERS L.P.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    (415) 525-8830

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    July 17, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 46124U107

      1   NAME OF REPORTING PERSON  
             
            BIOTECHNOLOGY VALUE FUND, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         4,630,461*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              4,630,461*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,630,461*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            8.8%*  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    * Includes 451,003 ADSs (as defined below), each of which represents one (1) Share (as defined below).

    2

    CUSIP No. 46124U107

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         4,630,461*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              4,630,461*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,630,461*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            8.8%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * Includes 451,003 ADSs, each of which represents one (1) Share.

    3

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BIOTECHNOLOGY VALUE FUND II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,321,861*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              3,321,861*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,321,861*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.3%*  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    * Includes 234,997 ADSs, each of which represents one (1) Share.

    4

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         3,321,861*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              3,321,861*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,321,861*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.3%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * Includes 234,997 ADSs, each of which represents one (1) Share.

    5

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CAYMAN ISLANDS  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         397,086*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              397,086*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            397,086*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            LESS THAN 1%*  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    * Includes 40 ADSs, each of which represents one (1) Share.

    6

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF PARTNERS OS LTD.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CAYMAN ISLANDS  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         397,086*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              397,086*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            397,086*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            LESS THAN 1%*  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    * Includes 40 ADSs, each of which represents one (1) Share.

    7

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP HOLDINGS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         7,952,322*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              7,952,322*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            7,952,322*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            15.2%*  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    * Includes 686,000 ADSs, each of which represents one (1) Share.

    8

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF PARTNERS L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         8,545,499*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              8,545,499*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,545,499*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.3%*  
      14   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    * Includes 686,040 ADSs, each of which represents one (1) Share.

    9

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            BVF INC.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         8,545,499*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              8,545,499*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,545,499*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.3%*  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    * Includes 686,040 ADSs, each of which represents one (1) Share.

    10

    CUSIP No. 46124U107

     

      1   NAME OF REPORTING PERSON  
             
            MARK N. LAMPERT  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         8,545,499*  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              0  
        10   SHARED DISPOSITIVE POWER  
               
              8,545,499*  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,545,499*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            16.3%*  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    * Includes 686,040 ADSs, each of which represents one (1) Share.

    11

    CUSIP No. 46124U107

     

    The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned (“Amendment No. 2”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.

    Item 5.Interest in Securities of the Issuer.

    Items 5(a) and (c) are hereby amended and restated to read as follows:

    (a)       The aggregate percentage of Shares reported owned by each person named herein is based on 52,477,188 Shares outstanding, which is the total number of Shares outstanding as reported in Exhibit 99.1 to the Issuer’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on May 30, 2024.

    As of the date hereof, (i) BVF beneficially owned 4,630,461 Shares, including 451,003 Shares underlying ADSs held by it, representing percentage ownership of approximately 8.8% of the Shares outstanding, (ii) BVF2 beneficially owned 3,321,861 Shares, including 234,997 Shares underlying ADSs held by it, representing percentage ownership of approximately 6.3% of the Shares outstanding, (iii) Trading Fund OS beneficially owned 397,086 Shares, including 40 Shares underlying ADSs held by it, representing percentage ownership of less than 1% of the Shares outstanding, and (iv) 196,091 Shares were held in the Partners Managed Account, representing percentage ownership of less than 1% of the Shares outstanding.

    BVF GP, as the general partner of BVF, may be deemed to beneficially own the 4,630,461 Shares beneficially owned by BVF, representing percentage ownership of approximately 8.8% of the Shares outstanding.

    BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,321,861 Shares beneficially owned by BVF2, representing percentage ownership of approximately 6.3% of the Shares outstanding.

    Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 397,086 Shares beneficially owned by Trading Fund OS, representing percentage ownership of less than 1% of the Shares outstanding.

    BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 7,952,322 Shares beneficially owned in the aggregate by BVF and BVF2, representing percentage ownership of approximately 15.2% of the Shares outstanding.

    Partners, as the investment manager of BVF, BVF2, Trading Fund OS and the Partners Managed Account and the sole member of Partners OS, may be deemed to beneficially own the 8,545,499 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and held in the Partners Managed Account, representing percentage ownership of approximately 16.3% of the Shares outstanding.

    BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 8,545,499 Shares beneficially owned by Partners, representing percentage ownership of approximately 16.3% of the Shares outstanding.

    Mr. Lampert, as a director and officer of BVF Inc. may be deemed to beneficially own the 8,545,499 Shares beneficially owned by BVF Inc., representing percentage ownership of approximately 16.3% of the Shares outstanding.

    12

    CUSIP No. 46124U107

    (c)       Except for the acquisition of Royalty Certificates of the Issuer described in Item 6 below, none of the Reporting Persons have entered into any transactions in the securities of the Issuer during the past sixty days.

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 is hereby amended to add the following:

    On July 17, 2024, the Issuer entered into subscription agreements (the “Royalty Certificate Subscription Agreements”) with certain investors, including certain Reporting Persons, pursuant to which the Issuer agreed to issue and sell, and such investors agreed to purchase and acquire, an aggregate of 201 royalty certificates (the “Royalty Certificates”), in a transaction exempt from registration under the Securities Act of 1933, as amended (the “Transaction”). In connection with the Transaction, the Reporting Persons purchased Royalty Certificates as follows: BVF (34 Royalty Certificates), BVF2 (26 Royalty Certificates), Trading Fund OS (3 Royalty Certificates) and the Partners Managed Account (1 Royalty Certificate), constituting a total of 64 Royalty Certificates.

    The subscription price of the Royalty Certificates is €100,000 per certificate. Settlement and delivery of the Royalty Certificates is expected to occur on or about July 22, 2024, subject to the satisfaction of customary closing conditions.

    The Royalty Certificates will provide the holders thereof with the right to an annual payment of royalties (“Royalties”) equal to 3% of the future net sales, if any, of the Issuer’s product candidate lanifibranor beginning on the fiscal year following the start of the sales of lanifibranor following the granting of the market authorization for lanifibranor in (i) the United States of America, (ii) the countries of the European Union or (iii) the United Kingdom, whichever occurs first, if at all.

    The Royalty Certificates will have a term of 14 years following the date of issue. In the event of a Merger (as defined in the Royalty Certificates), and upon the request of the Issuer, the holders of Royalty Certificates and the Issuer will negotiate the terms upon which the Issuer may purchase all of the then-outstanding Royalty Certificates; provided that neither the Issuer nor the holders of Royalty Certificates will have any obligation other than to conduct such negotiations in good faith. The Issuer may at any time repurchase in full the Royalty Certificates by paying a price to be agreed between the Issuer and the holders of the Royalty Certificates. The Issuer may also redeem the Royalty Certificates from each holder, subject to offering such redemption to every holder. The Issuer also has a pre-emptive right in the event of the sale of Royalty Certificates by a holder.

    In connection with the entry into the Royalty Certificate Subscription Agreements, the investors party thereto have agreed not to sell, transfer or otherwise dispose of the Royalty Certificates for a period of six months following the date of closing, subject to certain specified exceptions.

    The Royalty Certificates do not confer any additional financial rights besides the right to payment of Royalties referred to above. Specifically, the Royalty Certificates do not grant any financial rights on any other products that may be developed by the Issuer beyond lanifibranor.

    In addition, the Royalty Certificates do not entitle any holder thereof to vote or be deemed the holder of any other securities of the Issuer, nor do they confer upon any holder the rights of a stockholder of the Issuer or the right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or give or withhold consent to any corporate action or other actions affecting stockholders or to receive dividends or subscription rights or otherwise.

    13

    CUSIP No. 46124U107

    The foregoing description of the Royalty Certificate Subscription Agreements and the terms and conditions of the Royalty Certificates are qualified in their entirety by reference to the form of Royalty Certificate Subscription Agreement, a copy of which is referenced as Exhibit 99.1 hereto and is incorporated by reference herein.

    Item 7.Material to be Filed as Exhibits.

    Item 7 is hereby amended to add the following exhibit:

    99.1Form of Royalty Certificate Subscription Agreement, dated as of July 17, 2024 (incorporated by reference to Exhibit 99.1 of the Issuer’s Form 6-K, filed with the SEC on July 18, 2024).

     

     

    14

    CUSIP No. 46124U107

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: July 19, 2024

    BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
         
    By: BVF I GP LLC., its general partner      
          By: BVF Partners L.P., its investment manager
    By:

    /s/ Mark N. Lampert

      By: BVF Inc., its general partner
      Mark N. Lampert      
      Chief Executive Officer   By: /s/ Mark N. Lampert
            Mark N. Lampert
            President
    BVF I GP LLC      
             
    By: /s/ Mark N. Lampert   BVF GP HOLDINGS LLC
      Mark N. Lampert      
      Chief Executive Officer   By: /s/ Mark N. Lampert
            Mark N. Lampert
            Chief Executive Officer
    BIOTECHNOLOGY VALUE FUND II, L.P.    
             
    By: BVF II GP LLC, its general partner   BVF PARTNERS L.P.
             
    By:

    /s/ Mark N. Lampert

      By: BVF Inc., its general partner
      Mark N. Lampert      
      Chief Executive Officer   By: /s/ Mark N. Lampert
            Mark N. Lampert
            President
    BVF II GP LLC      
             
    By: /s/ Mark N. Lampert   BVF INC.
      Mark N. Lampert      
      Chief Executive Officer   By: /s/ Mark N. Lampert
            Mark N. Lampert
            President
    BVF PARTNERS OS LTD.      
             
    By: BVF Partners L.P., its sole member   /s/ Mark N. Lampert
    By: BVF Inc., its general partner   MARK N. LAMPERT
             
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert      
      President    

     

    15

    Get the next $IVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    3/17/2023$27.00Buy
    Stifel
    11/15/2022Buy → Sell
    Societe Generale
    11/22/2021$40.00 → $42.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 9:00:40 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 8:54:43 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      7/19/24 4:30:23 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Inventiva with a new price target

      TD Cowen initiated coverage of Inventiva with a rating of Buy and set a new price target of $10.00

      2/21/25 8:15:44 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Inventiva with a new price target

      UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00

      11/12/24 7:43:33 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Inventiva with a new price target

      Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00

      10/27/23 7:43:43 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

      Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the Company's Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will present a corporate overview during a fireside chat at the Jefferies Global Healthcare Conference which will take place in New York on June 4th at 10:30am ET.   The fireside chat will be webcast live and will be access

      5/27/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva reports 2025 First Quarter Financial Information¹

      Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues. Key Financial Results Cash, cash equivalents and deposits As of March 31, 2025, the Company's cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024. The decrease of €28.7 million is  

      5/23/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

      Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the results of the votes of its Combined Shareholders' Meeting.   The Combined Shareholders' Meeting was held on Thursday May 22, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Frédéric Cren, Chief Executive Officer and cofounder of Inventiva. Mr. Frederic Cren proceeded to the usual formalities of the opening of the meetin

      5/23/25 2:00:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

      Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.   Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH.   Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica

      12/16/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

      Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomized in the NATiV3 study evaluating lanifibranor for the treatment of noncirrhotic MASH, with completion of enrollment projected in 1H 2025.Appointment to the Board of Directors of Mark Pruzanski, MD,

      10/14/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the nomination of Andre Turenne as Director

      Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne's appointment will be submitted to the shareholders for ratification at the next general shareholder meeting. Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: "We are extre

      3/28/24 3:00:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Financials

    Live finance-specific insights

    See more
    • Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

      Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

      5/5/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva reports its 2024 full year results and provides a business update

      Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

      3/26/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

      Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

      3/19/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    SEC Filings

    See more
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/23/25 6:05:05 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/23/25 6:05:06 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/22/25 8:32:34 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care